Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1995-6-22
|
| pubmed:abstractText |
The study was undertaken to determine whether acromegalic patients with mean growth hormone (GH) concentrations of 2-5 micrograms/l have biochemically active disease following pituitary surgery or radiotherapy. 22 patients with acromegaly, 22 post surgery, 19 post radiotherapy had GH concentrations estimated during: (i) an oral glucose tolerance test (OGTT), (ii) a standard TRH test and (iii) 20 minute sampling for 8 hours. IGF-1 concentrations were measured. 6 normal subjects were also studied. Patients were divided into 3 groups on the basis of their mean GH concentration during the 8 hour sampling, > 5 micrograms/l, 2-5 micrograms/l, < 2 micrograms/l. Patients with mean GH concentrations of 2-5 micrograms/l (n = 6) had biochemically active disease: all had inadequate suppression of GH after OGTT, 5 had elevated IGF-1 concentrations, 4 had a paradoxical response to TRH. Patients with mean GH concentrations > 5 micrograms/l (n = 6) all had inadequate suppression after OGTT, 5 of 6 had increased IGF-1 concentrations, and 5 had abnormal responses to TRH. Of patients with mean GH concentrations < 2 micrograms/l (n = 10), 2 had elevated IGF-1 levels, 5 had abnormal responses to TRH and 4 inadequate GH suppression after OGTT. GH pulse number was similar in the three groups and GH pulse amplitude was significantly higher in those with GH > 5 micrograms/l compared to the other groups. In conclusion patients with GH concentrations of 2-5 micrograms/l have biochemically active disease and should be considered for further therapy after hypophysectomy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0018-5043
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
185-8
|
| pubmed:dateRevised |
2009-2-19
|
| pubmed:meshHeading |
pubmed-meshheading:7750902-Acromegaly,
pubmed-meshheading:7750902-Adult,
pubmed-meshheading:7750902-Aged,
pubmed-meshheading:7750902-Female,
pubmed-meshheading:7750902-Glucose Tolerance Test,
pubmed-meshheading:7750902-Growth Hormone,
pubmed-meshheading:7750902-Humans,
pubmed-meshheading:7750902-Insulin-Like Growth Factor I,
pubmed-meshheading:7750902-Male,
pubmed-meshheading:7750902-Middle Aged,
pubmed-meshheading:7750902-Pituitary Neoplasms,
pubmed-meshheading:7750902-Reference Values,
pubmed-meshheading:7750902-Thyrotropin-Releasing Hormone
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Do "so-called" normal growth hormone concentrations (2-5 micrograms/l) indicate cure in acromegaly?
|
| pubmed:affiliation |
Department of Medicine, University of Cape Town, South Africa.
|
| pubmed:publicationType |
Journal Article
|